Zimmer Biomet (ZBH)
NYSEHealth CareMedical DevicesSnapshot 2026-07-08
$87.56-2.07%
Close 2026-07-08 · 1-day change
Reading ZBH? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ZBH free→NYSEHealth CareMedical DevicesSnapshot 2026-07-08
Reading ZBH? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ZBH free→Zimmer Biomet grows revenue about 3% to 4.5% in 2026. Adjusted EPS is raised to about $8.47 per share. The company plans to repurchase up to $1 billion of shares in 2026. Recent acquisitions expand product offerings and support growth.
Growth faces headwinds that may slow revenue below 3%. Management changes and new debt raise uncertainty. Profit margins and EPS could weaken if execution falters.
The stock price is about 25% below our fair value near $120. Analysts expect roughly 3% revenue growth. Our view is slightly more optimistic on growth and EPS than consensus.
Breaks if: Adjusted EPS falls below $8.40 in FY26
Zimmer Biomet has raised its adjusted EPS guidance for the year 2026.
Stated in 2 of last 2 quarters. EPS guidance increased from $8.30-$8.45 in 2026-Q1 to $8.40-$8.55 in 2026-Q2. The company is delivering on its commitment to enhance EPS guidance, reflecting confidence in its financial performance.
Breaks if: Repurchases fall significantly short of $1 billion in FY26
Zimmer Biomet plans to repurchase up to $1 billion of its common stock during fiscal year 2026.
Breaks if: YoY revenue growth falls below 2.5% in FY26
Zimmer Biomet aims for a reported revenue change of 2.5% to 4.5% for the year 2026.
Standing thesis, reviewed periodically — not a price target or advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“We are raising our adjusted EPS guidance and free cash flow expectations for the year.”
“Adjusted Diluted EPS (2) $8.30 - $8.45”